Intelligent Bio Solutions (INBS) announced the submission of its 510(k) premarket notification to the US Food and Drug Administration, FDA, for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System, FDSS, an innovative, rapid and pain-free method for drug screening. The submission represents a critical milestone on the Company’s path to realizing its goal of entering the US market with its drug testing solution in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Releases Business Operations Presentation
- Intelligent Bio Solutions Advances Fingerprint Drug Testing
- Intelligent Bio completes method comparison study of Fingerpriinting system
- Intelligent Bio Solutions Announces Study Results and Stock Sale
- Intelligent Bio Solutions announces ‘strong initial results’ from PK study